PET/CT imaging for evaluation of multimodal treatment efficacy and toxicity in advanced NSCLC—current state and future directions
C Eze, NS Schmidt-Hegemann, LM Sawicki… - European journal of …, 2021 - Springer
Purpose The advent of immune checkpoint inhibitors (ICIs) has revolutionized the treatment
of advanced NSCLC, leading to a string of approvals in recent years. Herein, a narrative …
of advanced NSCLC, leading to a string of approvals in recent years. Herein, a narrative …
Prognostic value of 18F-FDG PET/CT in patients with advanced or metastatic non-small-cell lung cancer treated with immune checkpoint inhibitors: A systematic …
T Ling, L Zhang, R Peng, C Yue, L Huang - Frontiers in Immunology, 2022 - frontiersin.org
Purpose This study aimed to investigate the value of 18F-fluorodeoxyglucose positron
emission tomography/computed tomography (18F-FDG PET/CT) in predicting early …
emission tomography/computed tomography (18F-FDG PET/CT) in predicting early …
Baseline metabolic tumor burden on FDG PET/CT scans predicts outcome in advanced NSCLC patients treated with immune checkpoint inhibitors
Purpose We aimed to evaluate if imaging biomarkers on FDG PET are associated with
clinical outcomes in patients with advanced non-small cell lung cancer (NSCLC) treated with …
clinical outcomes in patients with advanced non-small cell lung cancer (NSCLC) treated with …
[HTML][HTML] Baseline total metabolic tumour volume on 2-deoxy-2-[18F] fluoro-d-glucose positron emission tomography-computed tomography as a promising biomarker …
FG Dall'Olio, D Calabrò, N Conci, G Argalia… - European Journal of …, 2021 - Elsevier
Abstract Introduction Immune checkpoint inhibitors (ICIs) have become the standard of care
in the management of advanced non–small cell lung cancer (NSCLC). Nevertheless, only a …
in the management of advanced non–small cell lung cancer (NSCLC). Nevertheless, only a …
PET-based volumetric biomarkers for risk stratification of non-small cell lung cancer patients
Despite the recent advances in lung cancer biology, molecular pathology, and treatment,
this malignancy remains the leading cause of cancer-related death worldwide and non …
this malignancy remains the leading cause of cancer-related death worldwide and non …
Metabolic factors associated with the prognosis of oligometastatic patients treated with stereotactic body radiotherapy
RJ Klement, RA Sweeney - Cancer and Metastasis Reviews, 2023 - Springer
Over the past two decades, it has been established that cancer patients with
oligometastases, ie, only a few detectable metastases confined to one or a few organs, may …
oligometastases, ie, only a few detectable metastases confined to one or a few organs, may …
The utility of 18F-FDG PET/CT for predicting the pathological response and prognosis to neoadjuvant immunochemotherapy in resectable non-small-cell lung cancer
R Guo, W Yan, F Wang, H Su, X Meng, Q Xie, W Zhao… - Cancer Imaging, 2024 - Springer
Objective To evaluate the potential utility of 18F-FDG PET/CT to assess response to
neoadjuvant immunochemotherapy in patients with resectable NSCLC, and the ability to …
neoadjuvant immunochemotherapy in patients with resectable NSCLC, and the ability to …
Increased CD8+ CD28+ T cells independently predict better early response to stereotactic ablative radiotherapy in patients with lung metastases from non-small cell …
Background Stereotactic ablative radiotherapy (SABR) shows a remarkable local control of
non-small cell lung cancer (NSCLC) metastases, partially as a result of host immune status …
non-small cell lung cancer (NSCLC) metastases, partially as a result of host immune status …
The combination of radiotherapy with immunotherapy and potential predictive biomarkers for treatment of non-small cell lung cancer patients
L Meng, J Xu, Y Ye, Y Wang, S Luo… - Frontiers in Immunology, 2021 - frontiersin.org
Radiotherapy is an effective local treatment modality of NSCLC. Its capabilities of eliminating
tumor cells by inducing double strand DNA (dsDNA) damage and modulating anti-tumor …
tumor cells by inducing double strand DNA (dsDNA) damage and modulating anti-tumor …
Stereotactic ablative radiation therapy for pulmonary recurrence-based oligometastatic non-small cell lung cancer: survival and prognostic value of regulatory T cells
C Liu, B Sun, X Hu, Y Zhang, Q Wang, J Yue… - International Journal of …, 2019 - Elsevier
Purpose We evaluated survival of patients with pulmonary recurrence–based
oligometastatic non-small cell lung cancer (NSCLC) whose lesions were all treated with …
oligometastatic non-small cell lung cancer (NSCLC) whose lesions were all treated with …